drugset
drugset / Trial / NCT07619183

A Study to Evaluate the Multiple Dose Ascending of PG-033 in Healthy Adult Participants.

NCT07619183 ↗

Phase 1 Not yet recruiting 30 enrolled Prime Gene Therapeutics Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) profiles of multiple ascending oral doses(MAD) of PG-033 by directly comparing it with placebo.

Timeline

Start
2026-06-04
Primary completion
2026-09-30
Completion
2026-12-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator PG-033 Unknown 20 mg Oral
Comparator PG-033 Unknown 60 mg Oral
Comparator PG-033 Unknown 90 mg Oral

Indications

neurodermatitis